The overarching goal of this present study was to validate the diagnostic accuracy of NULISA-quantified plasma p-tau biomarkers for the detection of Alzheimer’s disease Aβ and tau pathology via head-to-head comparisons with Simoa immunoassay-based methods. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.